Shelbi Burtt BSN, RN, OCN

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
Authored Items
Oncology Nursing Experience in Phase 3 iLLUMINATE: First-Line Ibrutinib-Obinutuzumab Versus Chlorambucil-Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Shelbi Burtt BSN, RN, OCN, Jessica Scott, RN, BSN, OCN, Cathy Zhou, MS, Lori Styles, MD, David Arthur, PhD, Bertrand Anz, MD, Ian W. Flinn, MD, PhD
November 2019 Vol 10, No 11
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the US for CLL/SLL treatment, including in combination with obinutuzumab.
Last modified: September 16, 2020

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512